Celecoxib for rheumatoid arthritis.
Megeff
C E
CE
Saint Louis University Family Practice Residency and Saint Louis College of Pharmacy, USA. carla.megeff@scott.af.mil
Strayer
S M
SM
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000139:chemically induced*; D011720:Pyrazoles; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D009288:Naproxen; D000068579:Celecoxib